Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Not Applicable

Recruiting

• Conditions: Plasma Cell Leukemia in Relapse; Relapsed and/or Refractory Multiple Myeloma
• Interventions: Other: Biological

• Registration Number: NCT05893693
• Lead Sponsor: Aibin Liang，MD，Ph.D.

Brief Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

Detailed Description

This is an open-label, single arm, dose-escalation clinical study, to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia

Study Timeline

• Study First Submitted: 2023-04-04
• Study Start: 2023-04-12
• Status Verified: 2023-05
• Study First Submitted QC: 2023-05-29
• Last Update Submitted: 2023-05-29
• Study First Posted: 2023-06-08
• Last Update Posted: 2023-06-08
• Primary Completion: 2026-01-01
• Study Completion: 2026-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. Patients and legally acceptable representative must have voluntarily signed ICF and willing to complete the study procedure, after fully understanding of the study.

2. Age ≥ 18 years and ≤ 75 years, male or female.

3. The patients, with MM or Plasma Cell Leukemia, who have received regimens and have medical records in the past.

4. According to the IMWG consensus for relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia, the disease is in a progressive state

5. Subjects should have measurable disease.

   5.1 Serum M protein ≥ 5 g / L;

   5.2 24-hour urinary M-protein ≥ 200 mg;

   5.3 The serum free light chain (sFLC) ratio was abnormal and the involved FLC ≥ 100mg/L in patients with light chain multiple myeloma whose serum or urinary M protein levels did not meet the assessable criteria.

   5.4 Circulating plasma cells ≥2%

6. Expected survival > 12 weeks.

7. Eastern Cooperative Oncology Group (ECOG) scores 0-1.

8. Subjects should have adequate function in hemostatic and liver and kidney.

9. Women of childbearing age must undergo a serum pregnancy test with negative results at screening and before lymphodepletion and be willing to use an effective and reliable method of contraception for at least 1 year after study treatment. All female subjects are prohibited from egg donation within 1 year after study treatment.

10. Men must be willing to use an effective and reliable method of contraception for at least 1 year after study treatment if they have sexual activity with women of childbearing potential. All male subjects are prohibited from sperm donation within 1 year after study treatment .

Exclusion Criteria

1. Pregnant or lactating women.
2. Subjects positive for any following tests: human immunodeficiency virus (HIV) antibody, Treponema pallidum (syphilis) antibody, CMV（IgM），EBV;
3. Active hepatitis B and/or active hepatitis C (HCV RNA positive); Those who are positive for hepatitis B surface antigen and/or core antibodies but whose HBV-DNA test is within normal limits may be enrolled.
4. Subjects with any uncontrolled active infection (Except for prophylactic treatment).
5. Subjects with AEs from previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤ 1, excluding hair loss and other events that the treating physician considers as tolerable.
6. Subjects who have received autologous BCMA CAR-T therapy
7. Subjects who have received allogeneic stem cell transplantation for MM.
8. Subjects who have received autologous stem cell transplantation less than 12 weeks before ICF.
9. Subjects who have received any anti-MM treatment 14 days before ICF; the subjects are eligible to participate in the study regardless of the radiotherapy end date if the radiation area less than 5% of whole body.
10. Subjects who have received systemic glucocorticoids within 7 days before infusion, except inhaled steroids.
11. Subjects who have been received live attenuated vaccine within 8 weeks or inactivated vaccine within 4 weeks before lymphodepletion.
12. Subjects have severe allergy history.
13. Subjects who have any uncontrolled disease conditions within 6 months prior to the screening.
14. LVEF < 50%
15. Blood oxygen saturation that can only be maintained at > 95% by oxygen inhalation.
16. Subjects known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other conditions that require long-term immunosuppressive therapy.
17. Subjects with malignant tumors that have not been cured in the past 5 years or at the same time, except for very low malignant tumors.
18. Subjects who have central nervous system (CNS) metastases or symptomatic CNS involvement.
19. Subjects who are unable or unwilling to comply with the requirements of clinical trial or other reasons that are not suitable for participating in the clinical trial.
20. Subjects who have received major surgery 2 weeks prior to the screening or plan to receive major surgery within 4 weeks after study treatment (excluding cataract and other local anesthesia).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CT0594CP CAR-T Cells [BCMA-UCAR-T (CT0594)andCD94-UCAR-T(CT7590) ]	Biological	CT0594CP

Primary Outcome Measures

Name	Time	Method
Safety and tolerability dose limiting toxicity	21-28 days	Safety and tolerability: dose limiting toxicity \[Time Frame: 21-28 days post administration of CT0594CP \]

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of CT0594CP CAR-T Cells (Cmax)	From first dose of study drug adminisration to end of treatment (up to 12 months)	peak plasma Concentration(Cmax), of after infusion CT0594CP CAR T Cells
Pharmacokinetics of CT0594CP CAR-T Cells (Tmax)	From first dose of study drug adminisration to end of treatment (up to 12 months)	peak plasma Concentration time(Tmax), of after infusion CT0594CP CAR T Cells
Pharmacokinetics of CT0594CP CAR-T Cells (AUC)	From first dose of study drug adminisration to end of treatment (up to 12 months)	area under the Plasma concentration versus time curve (AUC), of after infusion CT0594CP CAR T Cells
To evaluate the overall safety and tolerability of CT0594CP	From first dose of study drug administration to end of treatment (up to 12 months)	Post-treatment Adverse events (TEAE) and incidence, Special Concern Adverse Events (AESI) and incidence, treatment-related adverse events
To evaluate the initial efficacy of CT0594CP infusion in target subjects	From first dose of study drug administration to end of treatment (up to 12 months)	Overall response rate (ORR)、 Complete response/strict complete response (CR/sCR) rate、Response rates of VGPR and above were achieved; 、Duration of response (DOR)、Progression-free survival (PFS)、Overall survival (overall survival (OS)、Minimal residual disease (MRD) negative rate as measured by International Myeloma Working Group (IMWG) criteria after CT0594CP infusion

Trial Locations

Locations (1)

Shanghai Tongji Hospital; 🇨🇳 Shanghai, Shanghai, China